site

WIN site inhibitor 1 TFA is a WIN site of chromatin-associated WD repeat-containing protein 5 (WDR5) inhibitor (Kd: 0.1 nM).

The pp60 (v-SRC) Autophosphorylation Site, Phosphorylated is a phosphorylated peptide derived from an EGFR substrate, used as a critical tool for quantifying phosphorylated substrates in the screening of EGFR Kinase inhibitors.

ML318 is a biaryl nitrile PvdQ acylase inhibitor (IC50 of 20 nM for binding in the acyl-binding site). ML318 inhibits P. aeruginosa (PAO1) with IC50 of 19 μM. ML318 prevents pyoverdine production and limits the growth of P. aeruginosa under iron-limiting

PHD-1-IN-1 is a potent inhibitor of hypoxia-inducible factor prolylhydroxylase domain-1 (PHD-1) enzyme(IC50 = 0.034 μM).

Galanthamine N-Oxide, an alkaloid extracted from Zephyranthes concolor bulbs, effectively inhibits acetylcholinesterase (AChE) from electric eel with an EC50 of 26.2 μM. It acts as a significant inhibitor of substrate accommodation within the active sites of Torpedo californica AChE (TcAChE), human AChE (hAChE), and human BChE (hBChE) enzymes.

Crolibulin (EPC2407) is an inhibitor of small molecule tubulin polymerization.

(E/Z)-TG003 is a potent and ATP-competitive inhibitor of Cdc2-like kinase (Clk).

PNU112455A hydrochloride is an ATP site competetive inhibitor of CDK2 and CDK5,binds to the ATP site of CDK2 and CDK5 with Kms of 3.6 and 3.2 μM, respectively.

7-Chlorokynurenic acid (7-chloro-4-hydroxy-2-carboxyquinoline) is an effecitve and selective antagonist of NMDA receptor with IC50 of 0.56 μM for the glycine B coagonist site. 7-Chlorokynurenic acid inhibits the reuptake of glutamate into synaptic vesicles with a Ki of 0.59 μM and shows antinociceptive actions after neuraxial delivery.

Sigma-LIGAND-1 is a selective Sigma Receptor ligand with IC50 values of 16 nM and 19 nM at the DTG site and the PPP site, respectively, and a Ki of 4000 nM at the dopamine D2 receptor.

Itaconate-alkyne (ITalk) is a bioorthogonal probe for quantitative, site-specific chemoproteomic profiling of itaconate in inflammatory macrophages, facilitating biochemical evaluation and proteomic analysis of its direct targets.

4BP-TQS is an allosteric agonist of α7 nAChRs.

2',5'-Dideoxyadenosine is a potent and non-competitive adenylyl cyclase inhibitor, binding to the P-site with an IC50 of 3 μM.

Gefitinib (T1181) is an EGFR tyrosine kinase inhibitor, with IC50 of 2-37 nM in NR6wtEGFR cells. Gefitinib-D8 is a deuterium labeled Gefitinib.

Gefitinib is an EGFR tyrosine kinase inhibitor, with IC50 of 2-37 nM in NR6wtEGFR cells. Gefitinib N-oxide is the N-oxide derivative of Gefitinib.

WIN site inhibitor 1 is a WIN site of chromatin-associated WD repeat-containing protein 5 (WDR5) inhibitor (Kd: 0.1 nM), with anti-cancer activity.

L-701324 is an NMDA receptor with high affinity and selectivity for the glycine site, used as an orally active and long-acting anticonvulsant.

5,7-Dichlorokynurenic acid (5,7-dichlorokynurenic acid sodium) is an NMDA receptor antagonist.

ZL0590 is an effective and selective inhibitor of BD1-BRD4 (IC50 = 90 nM) with anti-inflammatory activities.

OGG1-IN-08 (OGG1-IN-O8) is an inhibitor of 8-oxoguanine DNA glycosylase 1 (OGG1;IC50 : 0.35 μM)

S1H, a synthetic peptide mimetic of human growth hormone amino acids 36-51, acts as an antagonist to the growth hormone receptor. It forms an α-helical structure in solution and inhibits STAT5 phosphorylation triggered by human growth hormone in SK-MEL-28 and MALME-3M melanoma cell lines, as well as prolactin in IM-9 B cell lymphocytes, at concentrations of 100 and 200 nM.

Tyrosine Protein Kinase Substrate is a polypeptide molecule with the sequence RRLIEDNEYTARG.

(R)-(+)-HA-966 ((+)-HA-966) is a partial agonist/antagonist of glycine site of the N-methyl-D-aspartate (NMDA) receptor complex. (R)-(+)-HA-966 selectively blocks the activation of the mesolimbic dopamine system by amphetamine, has the potential for neuro

H1-7 (histone H1 phosphorylation site), a synthetic polypeptide, serves as a PKA substrate and demonstrates utility in various PKA substrate applications [1] [2].